ghk-cu tolerance or desensitization or loss of effectiveness long-term use or downregulation ghk-cu tolerance or desensitization ghk-cu receptor downregulation or desensitization

Glatt Circle Suite 200 Woodburn, OR 97071 Get Directions All three of our clinic locations are designated as Tier 5 Patient Centered Primary Care Homes (PCPCH) through the Oregon Health Authority (OHA)

FOXO4-DRI Key Research Facts Full name: FOXO4 D-Retro-Inverso peptide (FOXO4-DRI) Classification: Cell-penetrating senolytic peptide FOXO4/p53 protein-protein interaction inhibitor Design: D-retro-inverso isoform of FOXO4s p53-binding domain reversed sequence with all D-amino acids Binding target: p53 transactivation domain 2 (TAD2) displaces FOXO4 from the FOXO4-p53 complex Mechanism: FOXO4-DRI binds p53 TAD2 p53 nuclear exclusion p53 mitochondrial translocation BAX activation caspase-3 cleavage senescent cell-selective apoptosis Selectivity basis: FOXO4 is upregulated in senescent cells but expressed at low levels in most non-senescent adult cells selectivity is mechanistically conferred D-amino acid advantage: Proteolytic stability resistant to intracellular peptidases that would rapidly degrade equivalent L-amino acid sequences Structural characterisation: NMR structural models of FOXO4-DRI/p53TAD2 complex resolved (Nature Communications, 2025) confirms disordered-to-ordered transition upon binding Research cell types studied: IMR90 fibroblasts, TM3 Leydig cells, endothelial cells, chondrocytes, keloid fibroblasts, HCT116 cancer cells In vitro working concentration: 25 M used in multiple published studies for senescent cell apoptosis induction What Does FOXO4-DRI Do in Research

Analytical guidelines such as ICH Q2(R2) discuss validation elements for procedures used to measure identity, purity, impurities, and other attributes [11]

2025, doi: 10.1007/s12178-025-09990-7

Reference: Kleinman HK & Sosne G (2012)